Cervical Cancer Chemoradiotherapy Outcomes with Prophylactic G-CSF

240 patients with locally advanced cervical cancer were analyzed to evaluate the impact of primary prophylaxis with pegylated G-CSF during concurrent chemoradiotherapy. The retrospective cohort study, authored by Qiang Du and posted in April 2026, compared an intervention group of 80 patients to a control group of 160 patients over a median follow-up of 53.5 months. It measured outcomes including severe neutropenia rates, treatment interruptions, chemotherapy completion, and survival.

Use Cases

• Analyze the association between prophylactic PEG-rhG-CSF use and the rate of grade 3-4 neutropenia (22.5% vs. 42.5%) in the patient cohort.
• Model the relationship between G-CSF prophylaxis and the frequency of radiotherapy interruptions exceeding 5 days (6.3% vs. 16.9%).
• Investigate the correlation between treatment group assignment and progression-free survival (HR, 0.660) over the 53.5-month follow-up period.
• Assess the impact of heterogeneous platinum-based chemotherapy regimens, which were included as a covariate in the adjusted analyses.

Strengths

• Study includes 240 patients, providing a substantive cohort for analysis.
• Median follow-up period of 53.5 months allows for longitudinal assessment of survival outcomes.
• Analysis adjusted for real-world regimen heterogeneity, increasing clinical relevance.

Limitations

• Dataset is small at 335.0 KB, indicating limited raw data, likely consisting of summary results and manuscript text.
• Data is retrospective and observational, limiting causal inference.
• Overall survival benefit showed only a trend (p=0.094), not statistical significance.

Provenance

Source

Qiang Du via figshare.

Collection Method

Retrospective cohort study of patient medical records.

Time Range

Study period not specified; median patient follow-up was 53.5 months.

Freshness

Last updated in April 2026.